<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03105193</url>
  </required_header>
  <id_info>
    <org_study_id>IPL/IVL</org_study_id>
    <nct_id>NCT03105193</nct_id>
  </id_info>
  <brief_title>Intravenous and Intraperitoneal Lignocaine for Perioperative Analgesia in Laparoscopic Colon Resections</brief_title>
  <official_title>Intravenous and Intraperitoneal Lignocaine for Perioperative Analgesia in Laparoscopic Colon Resections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Auckland, New Zealand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Auckland, New Zealand</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the analgesic effects of intraperitoneal lignocaine&#xD;
      (IPL) compared with intravenous lignocaine (IVL) after laparoscopic colon resections. We plan&#xD;
      to run a 2 group randomized, double blind, clinical trial which will look into morphine&#xD;
      consumption as the primary outcome.&#xD;
&#xD;
      Group 1 (IV lignocaine)- IV bolus of lignocaine and a 3 day post operative IV lignocaine&#xD;
      infusion. Intra peritoneal (IP) bolus of normal saline + 3 day post operative IP normal&#xD;
      saline infusion&#xD;
&#xD;
      Group 2 (IP lignocaine)- IV bolus of normal saline and a 3 day post operative IV normal&#xD;
      saline infusion. IP bolus of lignocaine + 3 day post operative IP lignocaine infusion&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over the last 20 years, laparoscopic colonic surgery has become an accepted first-line&#xD;
      treatment for colon cancer. A population-based study showed that laparoscopic colonic&#xD;
      resections can be performed with lower hospital costs up to 90 days after discharge when&#xD;
      compared to open surgery. Laparoscopic colonic resections have also been associated with&#xD;
      fewer postoperative complications and lower mortality.&#xD;
&#xD;
      New Zealand has one of the highest rates of bowel cancer in the world, and it is the second&#xD;
      highest cause of cancer deaths in New Zealand. With the implementation of a bowel screening&#xD;
      programme in New Zealand, the projected numbers of stage 1 bowel cancers are expected to&#xD;
      increase. More avenues to improve perioperative care need to be explored to improve patient&#xD;
      outcomes.&#xD;
&#xD;
      Controlling postoperative pain effectively has been shown to reduce the length of hospital&#xD;
      stay and improve patient/clinical outcomes. Opioids work as Î¼-receptor agonists in the spinal&#xD;
      cord and brain, and although opioids are excellent at reducing pain, they are associated with&#xD;
      nausea, vomiting, dizziness, decreased blood pressure, and urinary retention. Epidurals have&#xD;
      been incorporated into Enhanced Recovery After Surgery protocols for controlling&#xD;
      post-operative pain. However, epidurals are an invasive procedure with significant side&#xD;
      effects such as hypotension, urinary retention, respiratory depression, motor blockade and&#xD;
      rarely epidural abscess and meningitis. It has also been shown that up to 30 percent of&#xD;
      epidural catheters dislodge, block or leak. These complications have led to a movement&#xD;
      towards other regional analgesia techniques which allow local anaesthetic (LA) to target the&#xD;
      abdominal wound specifically.&#xD;
&#xD;
      Intraperitoneal local anaesthetic (IPLA) has shown promise in reducing pain after colonic&#xD;
      surgery with a meta-analysis9, and a recent IPLA colorectal study conducted at Counties&#xD;
      Manukau health showing that it reduces pain and opioid use over and above the effect of an&#xD;
      epidural10, which is primarily aimed at the abdominal wound. After an IPLA bolus serum local&#xD;
      anaesthetic levels are detectable within 2 minutes. Some studies show reduced early&#xD;
      postoperative pain and opioid consumption with intravenous lignocaine infusion alone. The&#xD;
      question remains however if there is a benefit from using intraperitoneal local anaesthetic&#xD;
      compared to administering it intravenously as the IPLA should block both the intraabdominal&#xD;
      wound, via a local action, and the skin wound via a systemic action.. This has been&#xD;
      investigated in four studies, however none of these studies compared intravenous local&#xD;
      anaesthetic (IVLA) and IPLA for colon resection.&#xD;
&#xD;
      The aim is that, by optimising analgesia regimes using local anaesthetic, we can improve&#xD;
      patient experience of pain and recovery thereby achieving an earlier discharge and early&#xD;
      recovery from surgery. This has significant economic benefits for all involved.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2018</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine consumption</measure>
    <time_frame>3 days</time_frame>
    <description>Total morphine consumption at day 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>0, 6, 12 hours and Postoperative day (POD) 1, 2, 3, 4 and 7</time_frame>
    <description>Pain scores using the visual analogue score (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Inflammatory Response (CRP and WBC)</measure>
    <time_frame>very morning post op starting day 1 until day 4 post op</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Local Anesthetic Level</measure>
    <time_frame>every morning post op starting day 1 until day 4 post op</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>Variable measure as it is dependent on the patients recovery after surgery. Cut off 3 weeks</time_frame>
    <description>The day that the patient is discharged will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return of bowel function</measure>
    <time_frame>Variable measure as it is dependent on the patients recovery after surgery. Cut off 3 weeks</time_frame>
    <description>Time to flatus, first bowel motion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmissions complications</measure>
    <time_frame>30 days post op</time_frame>
    <description>Readmissions complications will be recorded up to day 30 post op using the Clavien-Dindo Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical recovery scores (SRS)</measure>
    <time_frame>Up to 60 days post op</time_frame>
    <description>SRS questionnaires will be administered at day 1 till discharge then POD 14, 30 and 60</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Laparoscopic Colon Resection</condition>
  <condition>Perioperative Analgesia</condition>
  <arm_group>
    <arm_group_label>Intraperitoneal Lignocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP Lignocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous lignocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV lignocaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Saline bolus and infusion</intervention_name>
    <description>Intravenous bolus of normal saline at induction 3 day postoperative infusion of normal saline administered by ambit pump</description>
    <arm_group_label>Intraperitoneal Lignocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IP Saline bolus and infusion</intervention_name>
    <description>Intraperitoneal bolus of normal saline down first port site. 3 day post operative intraperitoneal infusion of normal saline via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.</description>
    <arm_group_label>Intravenous lignocaine</arm_group_label>
    <other_name>Lidocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV lignocaine bolus and infusion</intervention_name>
    <description>Intravenous lignocaine bolus at induction. 3 day postoperative IV infusion of lignocaine administered by ambit pump</description>
    <arm_group_label>Intravenous lignocaine</arm_group_label>
    <other_name>Lidocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IP Lignocaine bolus and infusion</intervention_name>
    <description>Intraperitoneal bolus of lignocaine down first port site. 3 day post operative intraperitoneal infusion of lignocaine via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.</description>
    <arm_group_label>Intraperitoneal Lignocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  consecutive consenting patients undergoing elective laparoscopic colonic resections&#xD;
             will be recruited from surgical outpatient clinics at Manukau Super Clinic.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  under 16 years of age&#xD;
&#xD;
          -  acute colonic resection&#xD;
&#xD;
          -  those with ASA &gt;= 4&#xD;
&#xD;
          -  previous adverse reaction/allergy to local anaesthetic,&#xD;
&#xD;
          -  surgery for rectal lesions which was defined as lesion within 15 cm of the anal verge&#xD;
&#xD;
          -  preoperative systemic steroid dependence&#xD;
&#xD;
          -  hepatic dysfunction, opioid use greater than 6 months&#xD;
&#xD;
          -  a diagnosis of Chronic Pain Syndrome&#xD;
&#xD;
          -  inability to consent or complete data scores in the study questionnaires due to&#xD;
             cognitive impairment and/or language barrier.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew G Hill</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Auckland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Manukau Surgical Centre, Middlemore Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>April 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Auckland, New Zealand</investigator_affiliation>
    <investigator_full_name>Andrew G Hill, MBChB, MD (Thesis), EdD, FACS, FRACS</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Colon surgery</keyword>
  <keyword>Lignocaine</keyword>
  <keyword>Lidocaine</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Local anaesthetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

